Company intelligence / Profile preview
NAYA Biosciences
Sarasota, Florida, USAnayabiosciences.com ↗
- Ownership
- Public · INVO
- Development stage
- Commercial
01
Overview
The company’s flagship product "INVOcell" is FDA-cleared and CE-marked as a first-in-class intravaginal culture system for fertility treatment. The company has expanded into clinical-stage therapeutics in oncology and autoimmune disease through its merger with NAYA Biosciences. Lead assets include NY‑303 in Phase I/II trials for hepatocellular carcinoma and NY‑338 targeting multiple myeloma and autoimmune indications.
- Therapeutic areas
- Women's HealthOncologyImmunology
- Modalities
- DeviceBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Ferring Pharmaceuticals – exclusive U.S. licensing agreement for the INVOcell device
Beyond the preview
Go deeper on NAYA Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAYA Biosciences.